Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Benzodiazepines and thienodiazepines

Flualprazolam

C17H12ClFN4 CAS 28910-91-0 Analytical reference material — not for human consumption
Flualprazolam, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
Flualprazolam
IUPAC name
8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Parent CAS number (reference)
28910-91-0
Molecular formula
C17H12ClFN4
Molecular weight
326.8 g/mol
InChIKey
MPZVLJCMGPYWQQ-UHFFFAOYSA-N
PubChem
CID 10359044
Source
PubChem
Verified synonyms & catalog abbreviations
Fluloprazolam

Verified Neurochemical & Toxicological Intelligence

Flualprazolam

Potent Hypnotic GABA-A Positive Allosteric Modulator Triazolobenzodiazepine
Verified PubChem & CAS Identity C17H12ClFN4 · CAS 28910-91-0 · CID 10359044
Calibrated Physical Form Precision Tablets · 1 Tablet = 1 mg
≥98% Analytical Purity Verified 326.8 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Very High
GABAₐ α₅ Amnestic / Cognitive Modulation High

2'-Fluoro derivative of alprazolam exhibiting sub-nanomolar binding affinity at GABA-A benzodiazepine sites with pronounced alpha1 hypnotic-amnestic efficacy.

Biotransformation & Active Metabolites

Metabolized via CYP3A4 to alpha-hydroxyflualprazolam and 4-hydroxyflualprazolam.

Temporal Pharmacokinetics

Potent Hypnotic GABA-A Positive Allosteric Modulator — Extremely potent per milligram: a single 1 mg tablet represents a strong hypnotic amount on the published scale (roughly 3–4x stronger by weight than Bromazolam or Etizolam), carrying steep anterograde amnesia and delusions-of-sobriety risk if stacked.

  1. Onset 15–40 min
  2. Peak Window 1.5–3 h
  3. Total Window 6–14 h
  4. Residual / Half-Life 12–24 h residual drowsiness

Extremely potent per milligram: a single 1 mg tablet represents a strong hypnotic amount on the published scale (roughly 3–4x stronger by weight than Bromazolam or Etizolam), carrying steep anterograde amnesia and delusions-of-sobriety risk if stacked.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
0.125 mg
Cognitive & Sensory

Subtle threshold receptor activity (Potent Hypnotic GABA-A Positive Allosteric Modulator).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
0.125–0.25 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
0.25–0.5 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
0.5–1 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
1.5+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Elevated Hazard — Avoid

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Caution / Receptor Attenuation

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Structural Isomer & Sibling Comparison

Extremely potent per milligram: a single 1 mg tablet represents a strong hypnotic amount on the published scale (roughly 3–4x stronger by weight than Bromazolam or Etizolam), carrying steep anterograde amnesia and delusions-of-sobriety risk if stacked.

Physicochemical Stability & Storage

Physical Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
DAT Dopamine transporter

DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.

GABAₐ GABA-A positive modulator

GABA-A is the main inhibitory receptor for the messenger GABA. A positive modulator does not replace GABA. It makes GABA's own signal stronger when GABA is already there.

NMDA NMDA glutamate channel

NMDA is a glutamate receptor that works like a gated channel. Ketamine-type and PCP-type cards cite it when papers describe that channel as blocked.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

T½ Half-life

Half-life is the time it takes a measured concentration to fall by half. After one half-life, half remains. After another, a quarter of the original measurement remains.

1 mg / µg Calibrated Physical Form (1 mg Tablets, µg Liquid, Crystal)

Milligram-scale benzodiazepines are supplied as 1 mg tablets (1 tablet = 1 mg), microgram lysergamides as dissolved liquid (µg), and standard compounds as pure crystal or powder.

OUN / Oddech Synergistic CNS & Respiratory Depression

Combining two central nervous system depressants (such as benzodiazepines, alcohol, GHB, or opioids) multiplies sedation and can suppress brainstem breathing drive.

Tolerancja × Cross-Tolerance

When exposure to one compound reduces sensitivity to other compounds that act on the same receptor family (for example across all 5-HT2A lysergamides or all GABA-A modulators).

Comprehensive Analytical & Toxicological Monograph

Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; CAS 28910-91-0, PubChem CID 10359044) is a triazolobenzodiazepine reference compound (C17H12ClFN4, 326.8 g/mol) classified pharmacologically as a Potent Hypnotic GABA-A Positive Allosteric Modulator. 2'-Fluoro derivative of alprazolam exhibiting sub-nanomolar binding affinity at GABA-A benzodiazepine sites with pronounced alpha1 hypnotic-amnestic efficacy. Metabolized via CYP3A4 to alpha-hydroxyflualprazolam and 4-hydroxyflualprazolam. In published observational and toxicological literature, threshold response is noted at 0.125 mg, light range at 0.125–0.25 mg, common reference range at 0.25–0.5 mg, strong intensity at 0.5–1 mg, and heavy/adverse territory at 1.5+ mg, with an onset of 15–40 min, peak window of 1.5–3 h, and total duration of 6–14 h (12–24 h residual drowsiness). Extremely potent per milligram: a single 1 mg tablet represents a strong hypnotic amount on the published scale (roughly 3–4x stronger by weight than Bromazolam or Etizolam), carrying steep anterograde amnesia and delusions-of-sobriety risk if stacked. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemical Architecture & Structural Profile

Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C17H12ClFN4 and a molar mass of 326.8 g/mol. The parent molecule is indexed under CAS registry number 28910-91-0 and in the NCBI PubChem database as CID 10359044 (Standard InChIKey: MPZVLJCMGPYWQQ-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Flualprazolam is indexed within the Benzodiazepines structural group. Triazolo/thienodiazepine reference compound; carries a high risk of synergistic respiratory depression if combined with opioids, alcohol, or other CNS depressants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Uncertain combinations (caution advised)